Pharmacotherapeutic group: immunostimulant herbal
ATC code: L03AX
Included in the drug substance polysaccharide have an immunostimulatory and anti-inflammatory effect.
Studies in humans and / or animals by parenteral administration and / or ingestion of Echinacea preparations immunobiological effect was observed: increase in the number of leukocytes and cells of the reticuloendothelial system of the spleen, there was an increase in phagocytic activity of granulocytes
Data not available.
Echinaceae purpurae herbae succus
Teva Pharmaceutical Enterprise Co., Ltd., Israel
One tablet contains
active substance – svezhetsvetuschey Echinacea purpurea herb dry extract 100.0 mg,
auxiliaries : colloidal silicon dioxide, sorbitol, sodium cyclamate, magnesium stearate.
- Prevention and treatment of common infections, viral and colds
Hypersensitivity to Echinacea purpurea plants of the Asteraceae family, or any other component of the formulation; use in progressive systemic disease (e.g., tuberculosis, sarcoidosis), diseases of the leukocyte system (e.g., leukemia or leykozopodobnye disease, leukemia), autoimmune diseases (inflammatory connective tissue diseases (collagen disease), multiple sclerosis), immune deficiency (AIDS, HIV infection) , immunosuppression (for example, after organ transplantation or bone marrow transplantation, chemotherapy for cancer), chronic viral diseases; hereditary fructose intolerance.
The drug is not recommended for use in children under the age of 12 years due to a lack of data on efficacy and safety in these patients.
In the application of echinacea preparations were observed:
- hypersensitivity reactions (rash, pruritus, facial edema, shortness of breath, dizziness, and decreased blood pressure, anaphylactic shock, Stevens-Johnson syndrome);
- on the part of the gastrointestinal tract: nausea, vomiting, and diarrhea;
- development of immune diseases (disseminated encephalitis, erythema nodosum, immune thrombocytopenia, Evans syndrome, Sjogren’s syndrome with renal tubular dysfunction) can be related to preparations containing echinacea;
- in patients with atopy may develop allergic reactions;
- with prolonged use (more than 8 weeks) may occur pathological changes in the blood (leukopenia).
The frequency of adverse reactions is unknown.
How to accept, acceptance rate and dosage
Tablets of the drug-Immunorm Teva can dissolve, chewed or swallowed with water. The drug is independent of food intake.
Adults and children over 12 years: 1 tablet 2-4 times a day
The drug-Immunorm Teva should be taken continuously for at least 10 days.
The duration of treatment should not exceed 8 weeks.
If treatment in patients receiving the drug over 5-7 days the symptoms persist or deterioration occurs, consult a doctor.
Store at a temperature not higher than 25 C.
Keep out of the reach of children!
Echinaceae purpurae herbae succus
Systematic studies of drug interactions Immunorm-Teva or preparations made from herbaceous parts of Echinacea purpurea with other drugs have not been conducted.
Formulations Echinacea purpurea may influence the activity of CYP3A isozymes CYPIA2 or cytochrome P450. The clinical relevance of this for products prepared from the grassy part of the plant, is not clear.
When the joint application of drugs, which elimination depends on the activity of CYP3A isozymes or CYPIA2 cytochrome P450, one can not exclude strengthening or weakening the effect of these drugs.
Not recommended simultaneous application with immunosuppressive drug.
Patients with atopy have an increased risk of anaphylactic shock.
The drug-Immunorm Teva contains sorbitol. Patients with rare hereditary fructose intolerance should not take the drug Immunorm-Teva. Each tablet contains 570 mg of sorbitol, which corresponds to 0.05 XE.
You should not use the drug Immunorm-Teva in children under 12 years of age, as insufficient data on efficacy and safety in this patient group.
In recurrent infections of the respiratory and urinary tract infections should consult your doctor.
Effects on ability to drive vehicles and mechanisms
Studies of the effect of the drug-Immunorm Teva on the ability to drive and the ability to service arrangements have not been conducted.
Pregnancy and lactation
Immunorm contraindicated during pregnancy and lactation (breastfeeding).
So far, cases of drug overdose Immunorm not identified.